Quick answer: latest quarter results, by ticker or company name

Arbutus Biopharma (ABUS) Q4 2023 Earnings Report

Comprehensive analysis of Arbutus Biopharma's financial performance for Q4 2023 with historical comparisons and future outlook.

Reported Q: Q4 2023 Rev YoY: -65.7% EPS YoY: +26.7% Move: +0.82%
Arbutus Biopharma
ABUS
$4.33 0.82%
Exchange NASDAQ Sector Healthcare Industry Biotechnology
Q4 2023
Published: Mar 5, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for ABUS

Reported

Report Date

Mar 5, 2024

Quarter Q4 2023

Revenue

2.15M

YoY: -65.7%

EPS

-0.11

YoY: +26.7%

Market Move

+0.82%

Previous quarter: N/A

Follow this company to get upcoming quarter alerts automatically.

Sign In To Follow

Earnings Highlights

  • Revenue of $2.15M down 65.7% year-over-year
  • EPS of $-0.11 increased by 26.7% from previous year
  • Gross margin of 83.3%
  • Net income of -19.31M
  • ""In 2023, we made several important strategic choices to best position Arbutus for long-term success." - Mike McElhaugh, Interim CEO" - Mike McElhaugh
ABUS
Arbutus Biopharma Corporation
Period Q4 2023
Currency USD
Report Type Quarterly Earnings
Generated Mar 30, 2026

Swipe to view all report sections

Executive Summary

Arbutus Biopharma Corporation reported a challenging Q4 2023, reflecting strategic shifts to focus on chronic Hepatitis B virus (HBV) treatments amid substantial operational expenditures. Revenue declined significantly to $2.1M, down 65.7% year-over-year, while total expenses totaled $22.7M, leading to a net loss of $19.3M for the quarter. Despite the rough financial performance, management expressed optimism regarding their pipeline developments and extended cash runway into Q1 2026 as a strategic fit for long-term success in the HBV therapeutic space. CEO Mike McElhaugh emphasized the company's commitment to achieving a functional cure for HBV, highlighting a multi-pronged therapeutic approach that positions Arbutus competitively within a complex market.

Key Performance Indicators

Revenue
Decreasing
2.15M
QoQ: -53.95% | YoY: -65.65%
Gross Profit
Decreasing
1.79M
83.26% margin
QoQ: -58.36% | YoY: -69.92%
Operating Income
Increasing
-20.52M
QoQ: 4.81% | YoY: 9.05%
Net Income
Increasing
-19.31M
QoQ: 3.94% | YoY: 15.71%
EPS
Increasing
-0.11
QoQ: 8.33% | YoY: 26.67%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q4 2024 1.57 -0.07 -26.6% View
Q3 2024 1.34 -0.10 -71.3% View
Q2 2024 1.73 -0.11 -62.9% View
Q1 2024 1.53 -0.10 -77.1% View
Q4 2023 2.15 -0.11 -65.7% View
Sign In To Follow Alerts

More ABUS Quarterly Reports

ABUS

Arbutus Biopharma
Q4 2024 Report
Arbutus Biopharma Corporation (ABUS) Q4 2024 Results: Financial Analysis and Market Insights...
Read full report

ABUS

Arbutus Biopharma
Q3 2024 Report
Arbutus Biopharma Corporation (ABUS) Q3 2024 Financial Results: Navigating Challenges with Promising Innovations...
Read full report

ABUS

Arbutus Biopharma
Q2 2024 Report
Arbutus Biopharma Corporation (ABUS) Q2 2024 Financial Results: Challenges and Progress in HBV Functional Cure Development...
Read full report

ABUS

Arbutus Biopharma
Q1 2024 Report
Arbutus Biopharma Corporation (ABUS) Q1 2024 Financial Results: Navigating Challenges with Promising Pipeline Developments...
Read full report

Q4 2023 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

View more companies and financial data in the Healthcare sector.

Explore Sector

ABUS Full Profile

View complete financial profile, news, and analysis for Arbutus Biopharma.

Company Profile

ABUS Financial Statements

Access detailed balance sheets, income statements, and cash flow reports.

View Financials

Earnings Calendar

Stay updated with upcoming earnings announcements from all public companies.

View Calendar